|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wanebo HJ, Kennedy BJ, Chmiel J, Steele G
Jr, Winchester D and Osteen R: Cancer of the stomach. A patient
care study by the American College of Surgeons. Ann Surg.
218:583–592. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Koeda K, Nishizuka S and Wakabayashi G:
Minimally invasive surgery for gastric cancer: The future standard
of care. World J Surg. 35:1469–1477. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Piunti A and Pasini D: Epigenetic factors
in cancer development: Polycomb group proteins. Future Oncol.
7:57–75. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gergely JE, Dorsey AE, Dimri GP and Dimri
M: Timosaponin A-III inhibits oncogenic phenotype via regulation of
PcG protein BMI1 in breast cancer cells. Mol Carcinog. 57:831–841.
2018. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Margueron R and Reinberg D: The polycomb
complex PRC2 and its mark in life. Nature. 469:343–349. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Suvà ML, Riggi N, Janiszewska M,
Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino
D, Cironi L, et al: EZH2 is essential for glioblastoma cancer stem
cell maintenance. Cancer Res. 69:9211–9218. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Riquelme E, Behrens C, Lin HY, Simon G,
Papadimitrakopoulou V, Izzo J, Moran C, Kalhor N, Lee JJ, Minna JD
and Wistuba II: Modulation of EZH2 expression by MEK-ERK or
PI3K-AKT signaling in lung cancer is dictated by different KRAS
oncogene mutations. Cancer Res. 76:675–685. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jung HY, Jun S, Lee M, Kim HC, Wang X, Ji
H, McCrea PD and Park JI: PAF and EZH2 induce Wnt/β-catenin
signaling hyperactivation. Mol Cell. 52:193–205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miranda TB, Cortez CC, Yoo CB, Liang G,
Abe M, Kelly TK, Marquez VE and Jones PA: DZNep is a global histone
methylation inhibitor that reactivates developmental genes not
silenced by DNA methylation. Mol Cancer Ther. 8:1579–1588. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mochizuki D, Misawa Y, Kawasaki H, Imai A,
Endo S, Mima M, Yamada S, Nakagawa T, Kanazawa T and Misawa K:
Aberrant epigenetic regulation in head and neck cancer due to
distinct EZH2 overexpression and dna hypermethylation. Int J Mol
Sci. 19(pii): E37072018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yao Y, Hu H, Yang Y, Zhou G, Shang Z, Yang
X, Sun K, Zhan S, Yu Z, Li P, et al: Downregulation of enhancer of
zeste homolog 2 (EZH2) is essential for the induction of autophagy
and apoptosis in colorectal cancer cells. Genes (Basel). 7:832016.
View Article : Google Scholar
|
|
13
|
Wei FZ, Cao Z, Wang X, Wang H, Cai MY, Li
T, Hattori N, Wang D, Du Y, Song B, et al: Epigenetic regulation of
autophagy by the methyltransferase EZH2 through an MTOR-dependent
pathway. Autophagy. 11:2309–2322. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hebert M, Potin S, Sebbagh M, Bertoglio J,
Bréard J and Hamelin J: Rho-ROCK-dependent ezrin-radixin-moesin
phosphorylation regulates Fas-mediated apoptosis in Jurkat cells. J
Immunol. 181:5963–5973. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Manalo DJ, Rowan A, Lavoie T, Natarajan L,
Kelly BD, Ye SQ, Garcia JG and Semenza GL: Transcriptional
regulation of vascular endothelial cell responses to hypoxia by
HIF-1. Blood. 105:659–669. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qi C, Zhang J, Chen X, Wan J, Wang J,
Zhang P and Liu Y: Hypoxia stimulates neural stem cell
proliferation by increasing HIF-1α expression and activating
Wnt/β-catenin signaling. Cell Mol Biol (Noisy-le-grand). 63:12–19.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pang B, Zheng XR, Tian JX, Gao TH, Gu GY,
Zhang R, Fu YB, Pang Q, Li XG and Liu Q: EZH2 promotes metabolic
reprogramming in glioblastomas through epigenetic repression of
EAF2-HIF1α signaling. Oncotarget. 7:45134–45143. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen Q, Cai J, Wang Q, Wang Y, Liu M, Yang
J, Zhou J, Kang C, Li M and Jiang C: Long noncoding RNA NEAT1,
regulated by the EGFR pathway, contributes to glioblastoma
progression through the WNT/β-catenin pathway by scaffolding EZH2.
Clin Cancer Res. 24:684–695. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Panousis D, Patsouris E, Lagoudianakis E,
Pappas A, Kyriakidou V, Voulgaris Z, Xepapadakis G, Manouras A,
Athanassiadou AM and Athanassiadou P: The value of TOP2A, EZH2 and
paxillin expression as markers of aggressive breast cancer:
relationship with other prognostic factors. Eur J Gynaecol Oncol.
32:156–159. 2011.PubMed/NCBI
|
|
21
|
Choi JH, Song YS, Yoon JS, Song KW and Lee
YY: Enhancer of zeste homolog 2 expression is associated with tumor
cell proliferation and metastasis in gastric cancer. Apmis.
118:196–202. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cheng LL, Itahana Y, Lei ZD, Chia NY, Wu
Y, Yu Y, Zhang SL, Thike AA, Pandey A, Rozen S, et al: TP53 genomic
status regulates sensitivity of gastric cancer cells to the histone
methylation inhibitor 3-deazaneplanocin A (DZNep). Clin Cancer Res.
18:4201–4212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chang CJ, Yang JY, Xia W, Chen CT, Xie X,
Chao CH, Woodward WA, Hsu JM, Hortobagyi GN and Hung MC: EZH2
promotes expansion of breast tumor initiating cells through
activation of RAF1-catenin signaling. Cancer Cell. 19:86–100. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Glazer RI, Hartman KD, Knode MC, Richard
MM, Chiang PK, Tseng CK and Marquez VE: 3-Deazaneplanocin: A new
and potent inhibitor of S-adenosylhomocysteine hydrolase and its
effects on human promyelocytic leukemia cell line HL-60. Biochem
Biophys Res Commun. 135:688–694. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu S, Liu F, Huang W, Gu L, Meng L, Ju Y,
Wu Y, Li J, Liu L and Sang M: MAGE-A11 is activated through
TFCP2/ZEB1 binding sites de-methylation as well as histone
modification and facilitates ESCC tumor growth. Oncotarget.
9:3365–3378. 2017.PubMed/NCBI
|
|
26
|
Sha M, Mao G, Wang G, Chen Y, Wu X and
Wang Z: DZNep inhibits the proliferation of colon cancer HCT116
cells by inducing senescence and apoptosis. Acta Pharm Sin B.
5:188–193. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang Y, Lin D and Taniguchi CM: Hypoxia
inducible factor (HIF) in the tumor microenvironment: Friend or
foe? Sci China Life Sci. 60:1114–1124. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Martin JD, Fukumura D, Duda DG, Boucher Y
and Jain RK: Reengineering the tumor microenvironment to alleviate
hypoxia and overcome cancer heterogeneity. Cold Spring Harb
Perspect Med. 6(pii): a0270942016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li DW, Dong P, Wang F, Chen XW, Xu CZ and
Zhou L: Hypoxia induced multidrug resistance of laryngeal cancer
cells via hypoxia-inducible factor-1α. Asian Pac J Cancer Prev.
14:4853–4858. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Borsi E, Terragna C, Brioli A, Tacchetti
P, Martello M and Cavo M: Therapeutic targeting of hypoxia and
hypoxia-inducible factor 1 alpha in multiple myeloma. Transl Res.
165:641–650. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lou JJ, Chua YL, Chew EH, Gao J, Bushell M
and Hagen T: Inhibition of hypoxia-inducible factor-1alpha protein
synthesis by DNA damage inducing agents. PLoS One. 5:e105222010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Michel G, Minet E, Ernest I, Durant F,
Remacle J and Michiels C: Molecular modeling of the
hypoxia-inducible factor-1 (HIF-1). Theor Chem Acc. 101:51–56.
1999. View Article : Google Scholar
|
|
33
|
Chang CJ, Yang JY, Xia W, Chen CT, Xie X,
Chao CH, Woodward WA, Hsu JM, Hortobagyi GN and Hung MC: EZH2
promotes expansion of breast tumor initiating cells through
activation of RAF1-β-catenin signaling. Cancer Cell. 19:86–100.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mahara S, Lee PL, Feng M, Tergaonkar V,
Chng WJ and Yu Q: HIFI-α activation underlies a functional switch
in the paradoxical role of Ezh2/PRC2 in breast cancer. Proc Natl
Acad Sci USA. 113:E3735–E3744. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tan J, Yang X, Zhuang L, Jiang X, Chen W,
Lee PL, Karuturi RK, Tan PB, Liu ET and Yu Q: Pharmacologic
disruption of Polycomb-repressive complex 2-mediated gene
repression selectively induces apoptosis in cancer cells. Genes
Dev. 21:1050–1063. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsang DP and Cheng AS: Epigenetic
regulation of signaling pathways in cancer: Role of the histone
methyltransferase EZH2. J Gastroenterol Hepatol. 26:19–27. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang J, Chen L, Han L, Shi Z, Zhang J, Pu
P and Kang C: EZH2 is a negative prognostic factor and exhibits
pro-oncogenic activity in glioblastoma. Cancer Lett. 356:929–936.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lu H, Sun J, Wang F, Feng L, Ma Y, Shen Q,
Jiang Z, Sun X, Wang X and Jin H: Enhancer of zeste homolog 2
activates Wnt signaling through downregulating CXXC finger protein
4. Cell Death Dis. 4:e7762013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Minde DP, Radli M, Forneris F, Maurice MM
and Rüdiger SG: Large extent of disorder in Adenomatous Polyposis
Coli offers a strategy to guard Wnt signalling against point
mutations. PLoS One. 8:e772572013. View Article : Google Scholar : PubMed/NCBI
|
